Analysts predict that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will report ($1.63) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.73) to ($1.55). Agios Pharmaceuticals posted earnings of ($1.59) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 2.5%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 7th.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.01) per share for the current year, with EPS estimates ranging from ($6.22) to ($5.90). For the next financial year, analysts expect that the firm will post earnings of ($5.97) per share, with EPS estimates ranging from ($6.10) to ($5.68). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The firm had revenue of $40.40 million during the quarter, compared to analysts’ expectations of $12.47 million. During the same quarter in the previous year, the company posted ($1.78) EPS. Agios Pharmaceuticals’s revenue was up 257.5% on a year-over-year basis.
AGIO stock traded down $0.41 during trading on Friday, hitting $73.56. The company had a trading volume of 503,600 shares, compared to its average volume of 446,340. Agios Pharmaceuticals has a 12 month low of $51.62 and a 12 month high of $99.82. The stock has a market capitalization of $4.20 billion, a PE ratio of -10.88 and a beta of 1.77.
In other Agios Pharmaceuticals news, insider Steven L. Hoerter sold 2,050 shares of the company’s stock in a transaction on Wednesday, July 25th. The shares were sold at an average price of $84.58, for a total transaction of $173,389.00. Following the completion of the sale, the insider now owns 2,050 shares in the company, valued at approximately $173,389. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $83.50, for a total transaction of $250,500.00. Following the sale, the insider now owns 60,196 shares of the company’s stock, valued at approximately $5,026,366. The disclosure for this sale can be found here. Insiders have sold a total of 28,627 shares of company stock valued at $2,212,296 in the last quarter. Corporate insiders own 3.02% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Tiverton Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $142,000. Strs Ohio bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $179,000. NewSquare Capital LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $182,000. Barrett Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $253,000. Finally, M&T Bank Corp bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at $293,000. Institutional investors own 93.64% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Featured Article: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.